To learn more about the top medical innovations for 2022, please visit https://cle.clinic/3GPe1c9

In the United States, 1 in 10 individuals has diabetes, which affects how the body processes food into energy. One potential therapy is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. Additionally, it slows digestion, resulting in individuals remaining full longer and eating less. Thus far, late phase III clinical trials reveal that the treatment significantly reduces hemoglobin A1C in type 2 diabetes and supports weight loss, making it potentially the most effective therapy for diabetes and obesity yet developed.

▶Share this video with others: https://youtu.be/kpXsJ8WyQI4

▶Subscribe to learn more about Cleveland Clinic:
https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1

#ClevelandClinic #MedicalInnovations